PASADENA, Calif.--(BUSINESS WIRE)--Sanguine Corporation (OTC Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells and numerous other areas requiring oxygen profusion, has released its latest shareholder letter. The letter will be available for download from the Company’s Website, which is www.sanguine-corp.com. An excerpt of the letter reads as follows:
